S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Sequential Hosts London Summit on AI-Driven Ingredient Discovery

On December 3, 2026, London’s King's Cross will host a gathering of R&D leaders tasked with navigating the intersection of artificial intelligence and clinical validation. Held at The Mills Fabrica, the Sequential-led forum marks a shift in how the beauty and biotechnology sectors verify the efficacy of next-generation ingredients.

Sequential Hosts London Summit on AI-Driven Ingredient Discovery
Photo: Bio & News

The one-day conference addresses a fundamental tension in the personal care market: as AI and multi-omics accelerate the pace of ingredient discovery, brands face mounting pressure to provide more rigorous scientific proof. Dr. Oliver Worsley, CEO and co-founder of Sequential, frames the event as a necessary response to a market demanding higher standards of evidence for bioengineered and longevity-focused products.

Keynote speaker Lieve Declercq of Proya Companies will anchor a program featuring insights from industry veterans, including Dr. Martin Pagac of dsm-firmenich, Christina Patane of Medik8, and John Milligan of The Honey Pot Company. The agenda moves beyond theoretical discussion, focusing on peer-to-peer knowledge sharing regarding real-world innovation cases and the application of multi-omics studies. With experts like Dr. Amir Jassim and S-Biomedic’s Veronika Oudova also contributing, the event aims to bridge the gap between discovery and consumer-facing validation.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!